158 related articles for article (PubMed ID: 37402091)
1. Dynamic interplay between corticosteroid treatment and the role of SRC-1 gene dysregulation in the progression of WHO-Grade 4 Astrocytoma.
Kurdi M; Fadul MM; Addas BMJ; Faizo E; Alkhayyat S; Bamaga AK; Alsinani T; Katib Y; Okal F; Maghrabi Y; Sabbagh AJ; Moshref R; Albalawi S; Alkhotani A; Halawa TF; Mulla N; Hakamy S; Baeesa S
J Neurooncol; 2023 Jul; 163(3):693-705. PubMed ID: 37402091
[TBL] [Abstract][Full Text] [Related]
2. The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma.
Butt N; Enani M; Alshanqiti M; Alkhotani A; Alsinani T; Karami MM; Fadul MM; Almansouri M; Hassan A; Baeesa S; Bamaga AK; Alkhayyat S; Faizo E; Kurdi M
Folia Neuropathol; 2023; 61(3):317-325. PubMed ID: 37818692
[TBL] [Abstract][Full Text] [Related]
3. Progesterone and estradiol effects on SRC-1 and SRC-3 expression in human astrocytoma cell lines.
Hernández-Hernández OT; Rodríguez-Dorantes M; González-Arenas A; Camacho-Arroyo I
Endocrine; 2010 Feb; 37(1):194-200. PubMed ID: 20963570
[TBL] [Abstract][Full Text] [Related]
4. The synergistic effect of IDH mutation and NDRG-2 dysregulation in the progression of WHO-grade 4 astrocytomas.
Kurdi M; Fadul MM; Alkhayyat S; Sabbagh AJ; Alsinani T; Alkhotani A; Mulla N; Mehboob R; Fathaddin AA; Bamaga A; Faizo E; Baeesa S
Pathol Res Pract; 2023 Aug; 248():154733. PubMed ID: 37536020
[TBL] [Abstract][Full Text] [Related]
5. Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines.
Hernández-Hernández OT; González-García TK; Camacho-Arroyo I
J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):127-34. PubMed ID: 22542550
[TBL] [Abstract][Full Text] [Related]
6. Estradiol increases cell growth in human astrocytoma cell lines through ERα activation and its interaction with SRC-1 and SRC-3 coactivators.
González-Arenas A; Hansberg-Pastor V; Hernández-Hernández OT; González-García TK; Henderson-Villalpando J; Lemus-Hernández D; Cruz-Barrios A; Rivas-Suárez M; Camacho-Arroyo I
Biochim Biophys Acta; 2012 Feb; 1823(2):379-86. PubMed ID: 22142990
[TBL] [Abstract][Full Text] [Related]
7. Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology.
Yang I; Han SJ; Sughrue ME; Tihan T; Parsa AT
J Neurosurg; 2011 Sep; 115(3):505-11. PubMed ID: 21663411
[TBL] [Abstract][Full Text] [Related]
8. From astrocytoma to glioblastoma: a clonal evolution study.
Yang F; Zou Y; Gong Q; Chen J; Li WD; Huang Q
FEBS Open Bio; 2020 May; 10(5):744-751. PubMed ID: 32069381
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
10. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
Vredenburgh JJ; Cloughesy T; Samant M; Prados M; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Das A; Friedman HS
Oncologist; 2010; 15(12):1329-34. PubMed ID: 21147867
[TBL] [Abstract][Full Text] [Related]
12. Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.
Feldheim J; Kessler AF; Feldheim JJ; Schulz E; Wend D; Lazaridis L; Kleinschnitz C; Glas M; Ernestus RI; Brandner S; Monoranu CM; Löhr M; Hagemann C
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563629
[TBL] [Abstract][Full Text] [Related]
13. Clinical effects of combined vasopressin--corticosteroid therapy in patients with recurrent grade 3 astrocytomas.
Bernard-Weil E; Landau-Ferey J; Ancri D; Pertuiset B
Neurochirurgia (Stuttg); 1972 Jul; 15(4):127-34. PubMed ID: 5069876
[No Abstract] [Full Text] [Related]
14. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
[TBL] [Abstract][Full Text] [Related]
15. High mobility group I-C protein in astrocytoma and glioblastoma.
Akai T; Ueda Y; Sasagawa Y; Hamada T; Date T; Katsuda S; Iizuka H; Okada Y; Chada K
Pathol Res Pract; 2004; 200(9):619-24. PubMed ID: 15497774
[TBL] [Abstract][Full Text] [Related]
16. High SRC-1 and Twist1 expression predicts poor prognosis and promotes migration and invasion by inducing epithelial-mesenchymal transition in human nasopharyngeal carcinoma.
Zhou J; Zhang J; Xu M; Ke Z; Zhang W; Mai J
PLoS One; 2019; 14(4):e0215299. PubMed ID: 30973923
[TBL] [Abstract][Full Text] [Related]
17. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice.
Weissenberger J; Steinbach JP; Malin G; Spada S; Rülicke T; Aguzzi A
Oncogene; 1997 May; 14(17):2005-13. PubMed ID: 9160879
[TBL] [Abstract][Full Text] [Related]
18. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.
da Fonseca CO; Linden R; Futuro D; Gattass CR; Quirico-Santos T
Arch Immunol Ther Exp (Warsz); 2008; 56(4):267-76. PubMed ID: 18726148
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome analysis reveals distinct gene expression profiles in astrocytoma grades II-IV.
Narsia N; Ramagiri P; Ehrmann J; Kolar Z
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):261-271. PubMed ID: 28452381
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the addition to corticoids of a growth factor (vasopressin) in the palliative therapy of malignant brain tumours.
Bernard-Weil E
Neurol Res; 1991 Jun; 13(2):94-102. PubMed ID: 1682847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
